Defibrotide for use in prophylaxis and/or treatment of Graft versus Host Disease (GVHD)
Defibrotide for use in prophylaxis and/or treatment of Graft versus Host Disease (GVHD) in humans is disclosed, preferably in hematopoietic stem cell transplantation (HSCT), more preferably allogeneic hematopoietic stem cell transplantation. Graft versus Host Disease of the invention (GVHD) can be acute aGVHD and/or chronic cGVHD, preferably acute.
1. A method of treating Graft versus Host Disease (GVHD) comprising:
administering to a human suffering from GVHD an amount of defibrotide sufficient to treat the GVHD; and
assessing a severity of the GVHD after administering the defibrotide.
2. The method of claim 1 , wherein the GVHD is acute or chronic.
3. The method of claim 2 , wherein the GVHD is acute.
4. The method of claim 1 comprising administering the defibrotide after a hematopoietic stem cell transplantation (HSCT).
5. The method of claim 4 , wherein the HSCT is an allogenic hematopoietic stem cell transplantation.
6. The method of claim 1 comprising administering the defibrotide in a dose ranging from 10 to 60 mg/kg per day.
7. The method of claim 6 comprising administering the defibrotide in a dose ranging from 20 to 40 mg/kg per day.
8. The method of claim 7 comprising administering the defibrotide in a dose of about 25 mg/kg per day.
9. The method of claim 1 comprising administering the defibrotide in a single or in repeated doses per day.
10. The method of claim 9 comprising administering the defibrotide in four doses per day.
11. The method of claim 1 comprising administering the defibrotide intravenously.
12. The method of claim 1 wherein the defibrotide is administered in an aqueous form.
13. The method of claim 1 , wherein the defibrotide was obtained by extraction from animal and/or vegetable tissues.
14. The method of claim 13 wherein the defibrotide was obtained by extraction from mammalian organs.